Figure 1. A, CT scan before empirical therapy for toxoplasmic encephalitis in an HIV-infected patient. B, CT scan 2.5 years later, after immune restoration with highly active antiretroviral therapy and 8 months without maintenance therapy for toxoplasmic encephalitis. Discontinuation of Secondary Prophylaxis for Toxoplasmic Encephalitis in Human Immunodeficiency Virus Infection After Immune Res...

BACKGROUND Studies of HIV-serodiscordant couples in stable sexual relationships have provided convincing evidence that antiretroviral therapy can prevent the transmission of HIV. We aimed to quantify the preventive effect of a public-sector HIV treatment and care programme based in a community with poor knowledge and disclosure of HIV status, frequent migration, late marriage, and multiple part...

Since the introduction of highly active antiretroviral therapy in the mid-1990s, antiretroviral therapy (ART) options have expanded considerably to include simpler, safer, and more tolerable regimens. This has included new options for initial regimens for treatment-naive patients as well as regimens for treatment-experienced patients with extensive drug resistance. Current regimen options are e...

1. What is the evidence of the effectiveness of peer-based programs to support adherence to highly active antiretroviral therapy (HAART)? 2. What population-related variables may be related to the success of peerbased adherence programs? (e.g. age, race, gender, drug use, homelessness) 3. What approaches have been successfully used to select peers and match them to participants in adherence sup...